With this signal of activity, our laboratory and others worldwide sought to enhance the effectiveness of IGF-1R targeted therapies by identifying synergistic drug combinations and determining biomarkers that predict which ES patients are most likely to respond. The gene discussed is IGF1R; the disease is Ewing sarcoma.